Ai Muroi1, Masashi Mizumoto2, Eiichi Ishikawa3, Satoshi Ihara3, Hiroko Fukushima4, Takao Tsurubuchi3, Hideyuki Sakurai2, Akira Matsumura3. 1. Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. a.muroi@md.tsukuba.ac.jp. 2. Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, 305-8575, Ibaraki, Japan. 3. Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. 4. Department of Pediatrics, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Abstract
INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is a type of brain malignancy with a very poor prognosis. Although various radiation and chemotherapy protocols have been attempted, only conventional radiotherapy has yielded improvements in survival. In this study, we aimed to compare proton therapy versus conventional photon radiotherapy in terms of the outcomes of pediatric patients with DIPG. METHODS: This retrospective review included 12 pediatric patients with newly diagnosed DIPG who received a total proton therapy dose of 54 Gy (relative biological effectiveness) in 30 fractions at the University of Tsukuba Hospital between 2011 and 2017 (proton group). We additionally reviewed the medical records of 10 patients with DIPG who previously underwent conventional photon radiotherapy at our institute (historical cohort). RESULTS: The median progression-free survival (PFS) duration was 5 months (range 1-11 months), and the 6-, 12-, and 18-month PFS rates were 50%, 33%, and 25%, respectively. The median overall survival (OS) duration was 9 months (range 4-48 months), and the 6-, 12-, 18-, and 24-month OS rates were 66.8%, 50%, 41%, and 20%, respectively. There were no significant differences in survival between the proton and historical groups (PFS, p = 0.169 and OS, p = 0.16). CONCLUSIONS: Proton therapy was well tolerated by the majority of patients. No severe adverse events, including radiation necrosis, were recorded. Proton therapy did not yield superior survival outcomes vs. conventional photon radiotherapy in patients with DIPG at our institution. Further research is needed to identify the factors associated with better survival in this population.
INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is a type of brain malignancy with a very poor prognosis. Although various radiation and chemotherapy protocols have been attempted, only conventional radiotherapy has yielded improvements in survival. In this study, we aimed to compare proton therapy versus conventional photon radiotherapy in terms of the outcomes of pediatric patients with DIPG. METHODS: This retrospective review included 12 pediatric patients with newly diagnosed DIPG who received a total proton therapy dose of 54 Gy (relative biological effectiveness) in 30 fractions at the University of Tsukuba Hospital between 2011 and 2017 (proton group). We additionally reviewed the medical records of 10 patients with DIPG who previously underwent conventional photon radiotherapy at our institute (historical cohort). RESULTS: The median progression-free survival (PFS) duration was 5 months (range 1-11 months), and the 6-, 12-, and 18-month PFS rates were 50%, 33%, and 25%, respectively. The median overall survival (OS) duration was 9 months (range 4-48 months), and the 6-, 12-, 18-, and 24-month OS rates were 66.8%, 50%, 41%, and 20%, respectively. There were no significant differences in survival between the proton and historical groups (PFS, p = 0.169 and OS, p = 0.16). CONCLUSIONS: Proton therapy was well tolerated by the majority of patients. No severe adverse events, including radiation necrosis, were recorded. Proton therapy did not yield superior survival outcomes vs. conventional photon radiotherapy in patients with DIPG at our institution. Further research is needed to identify the factors associated with better survival in this population.
Authors: Avani D Rao; Arif S Rashid; Qinyu Chen; Rosangela C Villar; Daria Kobyzeva; Kristina Nilsson; Karin Dieckmann; Alexey Nechesnyuk; Ralph Ermoian; Sara Alcorn; Shannon M MacDonald; Matthew M Ladra; Eric C Ford; Brian A Winey; Maria Luisa S Figueiredo; Michael J Chen; Stephanie A Terezakis Journal: Int J Radiat Oncol Biol Phys Date: 2017-07-29 Impact factor: 7.038
Authors: L R Mandell; R Kadota; C Freeman; E C Douglass; J Fontanesi; M E Cohen; E Kovnar; P Burger; R A Sanford; J Kepner; H Friedman; L E Kun Journal: Int J Radiat Oncol Biol Phys Date: 1999-03-15 Impact factor: 7.038
Authors: Geert O Janssens; Marc H Jansen; Selmer J Lauwers; Peter J Nowak; Foppe R Oldenburger; Eric Bouffet; Frank Saran; Karin Kamphuis-van Ulzen; Erik J van Lindert; Jolanda H Schieving; Tom Boterberg; Gertjan J Kaspers; Paul N Span; Johannes H Kaanders; Corrie E Gidding; Darren Hargrave Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-09 Impact factor: 7.038
Authors: Mark T Jennings; Richard Sposto; James M Boyett; L Gilbert Vezina; Emi Holmes; Mitchell S Berger; Carol S Bruggers; Janet M Bruner; Ka-Wah Chan; Kathryn E Dusenbery; Lawrence J Ettinger; Charles R Fitz; Deborah Lafond; David E Mandelbaum; Vicky Massey; Warren McGuire; Lee McNeely; Thomas Moulton; Ian F Pollack; Violet Shen Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: Z Gokce-Samar; P A Beuriat; C Faure-Conter; C Carrie; S Chabaud; L Claude; F Di Rocco; C Mottolese; A Szathmari; C Chabert; D Frappaz Journal: Childs Nerv Syst Date: 2016-07-05 Impact factor: 1.475
Authors: Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Hong In Yoon; Chan Woo Wee; Young Zoon Kim; Youngbeom Seo; Jung Ho Im; Yun Sik Dho; Kyung Hwan Kim; Je Beom Hong; Jae Sung Park; Seo Hee Choi; Min Sung Kim; Jangsup Moon; Kihwan Hwang; Ji Eun Park; Jin Mo Cho; Wan Soo Yoon; Se Hoon Kim; Young Il Kim; Ho Sung Kim; Kyoung Su Sung; Jin Ho Song; Min Ho Lee; Myung Hoon Han; Se Hoon Lee; Jong Hee Chang; Do Hoon Lim Journal: Brain Tumor Res Treat Date: 2021-04